GNH USA

Europe — EMA

Lamivudin/Zidovudin Mylan (Zidovudine, Lamivudine)

GNH USA supplies Lamivudin/Zidovudin Mylan (Lamivudine/Zidovudine), a nucleoside reverse transcriptase inhibitor for HIV-1 infection treatment.

Zidovudine, Lamivudine

Request sourcing

1
Pack/s

What is Zidovudine, Lamivudine?

Lamivudine, the active ingredient in Lamivudin/Zidovudin Mylan, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of HIV‑1 infection in both adults and children, often in combination with other antiretroviral agents.

GNH USA supplies Lamivudin/Zidovudin Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under strict GMP conditions. It is distributed through regulated channels to ensure consistent availability.

What is Zidovudine, Lamivudine used for?

Lamivudin/Zidovudin Mylan is used in antiretroviral therapy to control HIV‑1 replication.

- HIV‑1 infection (adults): reduces viral load and helps restore immune function. - HIV‑1 infection (children): improves growth parameters and decreases disease progression. - Prevention of mother‑to‑child transmission: lowers the risk of vertical HIV transmission when given to pregnant women.

What are the side effects of Zidovudine, Lamivudine?

The most frequently reported adverse reactions with lamivudine/zidovudine therapy involve hematologic and gastrointestinal systems.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: general tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe anemia: marked reduction in red blood cells. - Lactic acidosis: buildup of lactate causing metabolic disturbance. - Neutropenia: significant drop in neutrophil count. - Hypersensitivity reactions: rash, fever, or organ involvement.

What precautions apply to Zidovudine, Lamivudine?

Before initiating lamivudine/zidovudine, clinicians should consider several safety measures to minimize risks.

- Baseline laboratory assessment: obtain CBC, liver and renal function tests prior to therapy. - Hematologic monitoring: perform regular CBC to detect anemia or neutropenia. - Liver function monitoring: assess transaminases periodically, especially in patients with hepatic disease. - Pregnancy considerations: evaluate risk‑benefit ratio, as data are limited. - Avoid monotherapy: use in combination regimens to prevent resistance development. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

What does Zidovudine, Lamivudine interact with?

Lamivudin/Zidovudin Mylan may interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Didanosine: concurrent use increases risk of pancreatitis. - Stavudine: combined therapy heightens mitochondrial toxicity. - Alcohol: may exacerbate liver injury. - Other NRTIs: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Nevirapine: can raise lamivudine plasma levels. - Efavirenz: may affect zidovudine metabolism. - Rifampin: reduces zidovudine concentrations, potentially lowering antiviral effect.

Frequently asked questions

What is Lamivudin/Zidovudin Mylan used for?+
Lamivudin/Zidovudin Mylan is an antiretroviral medication indicated for the treatment of HIV‑1 infection in adults and children. It is typically prescribed as part of combination therapy to suppress viral replication, improve immune function, and reduce the risk of disease progression.
How does lamivudine work in this combination?+
Lamivudine is a nucleoside analogue that, after intracellular phosphorylation, mimics the natural nucleoside cytidine. When incorporated into viral DNA by HIV reverse transcriptase, it causes premature chain termination, halting viral DNA synthesis. In combination with zidovudine, it provides synergistic inhibition of the reverse transcription process.
What determines the dose of Lamivudin/Zidovudin Mylan?+
The appropriate dose of Lamivudin/Zidovudin Mylan is individualized by the prescribing healthcare professional based on factors such as the patient’s age, weight, renal and hepatic function, and the overall antiretroviral regimen. Patients should follow the prescriber’s instructions and not adjust the dose on their own.
Is Lamivudin/Zidovudin Mylan safe during pregnancy or breastfeeding?+
Safety data in pregnancy and lactation are limited. The medication may be used during pregnancy only if the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding decisions should be made in consultation with a healthcare provider, considering the benefits of maternal therapy and potential exposure to the infant.
How do I order Lamivudin/Zidovudin Mylan from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.
How does this product compare with other antiretroviral options?+
Lamivudin/Zidovudin Mylan combines two NRTIs, offering a well‑established efficacy profile and a lower barrier to resistance compared with single‑agent NRTI therapy. Compared with newer fixed‑dose combinations such as tenofovir/emtricitabine, it may have a different side‑effect spectrum, particularly a higher incidence of hematologic changes, but remains a viable option in many treatment guidelines.
What are the storage and handling requirements for Lamivudin/Zidovudin Mylan?+
The tablets should be stored at room temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.
How is Lamivudin/Zidovudin Mylan administered?+
Lamivudin/Zidovudin Mylan is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals to optimize absorption and reduce gastrointestinal discomfort.
What are the most serious risks associated with this medication?+
Serious adverse events include severe anemia, lactic acidosis, neutropenia, and hypersensitivity reactions that may involve rash, fever, or organ involvement. Patients should be monitored regularly for hematologic changes and any signs of metabolic disturbance, and they should seek immediate medical attention if severe symptoms develop.
Who should not use Lamivudin/Zidovudin Mylan?+
Individuals with known hypersensitivity to lamivudine, zidovudine, or any excipients in the formulation should avoid this product. It is also contraindicated in patients with severe bone‑marrow suppression or those who cannot be monitored regularly for hematologic toxicity. Clinicians must assess each patient’s medical history before initiating therapy.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Zidovudine, Lamivudine
Route
Oral Use
Manufacturer
Mylan Germany Gmbh
Origin
EU

Related products

Combivir

Combivir

Zidovudine, Lamivudine

Viiv Healthcare B.V.
EU
Combivir

Combivir

Zidovudine, Lamivudine

Viiv Healthcare B.V.
EU
Combivir

Combivir

Zidovudine, Lamivudine

Viiv Healthcare B.V.
EU
Combivir

Combivir

Zidovudine, Lamivudine

Viiv Healthcare B.V.
EU